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In this study, we describe the synthesis and in vitro evaluation of a series of peptidergic NMU ligands, 146 based on the naturally occurring NMU-8, as lead molecule. Although not naturally occurring in 147 human, NMU-8 was used as a lead since this peptide has the same C-terminal amino acid sequence as 148 human (h) NMU-25, and acts as a full agonist on the hNMURs without a loss in potency [26] . A first 149 set of analogs consisted of peptides with modifications described in literature on one hand and new 150 peptidergic ligands on the other hand. This approach allowed to verify if the previous reported activity 151 profiles on chicken crop smooth muscle preparations are similar when analyzed in the commonly used 152 human embryonic kidney 293 (HEK293) cell line. In a second set of NMU-analogs, steric bulk, 153 conformational constraints and 'peptoid' residues were introduced with the aim of developing peptides 154 with NMUR subtype selectivity, improved pharmacokinetics and enhanced proteolytic stability. The 155 effect of the introduced modifications on the affinity and activity at NMUR1 and NMUR2 was 156 evaluated on HEK293 cells transiently expressing one of these receptors. The effect of some keyM A N U S C R I P T
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Material and Methods 160
Chemicals 161 
2-(1H-
Benzotriazole
General 177
Analytical high performance liquid chromatography (HPLC) was carried out on an Agilent 1100 178 HPLC system with ChemStation for LC 3D software (Discovery ® BIO Wide Pore RP C18 column, 15 179 cm × 2.1 mm, 3 µm from Supelco, Bellefonte, Pennsylvania, USA). Gradient elution took place using 180 water with 0.1 % TFA and ACN with 0.1 % TFA as mobile phases. UV-detection was carried out at 181 215 nm. Peptides were purified using a preparative HPLC apparatus from Gilson with Unipoint 182 software package (Discovery ® BIO Wide Pore C18 column, 25 cm × 21.2 mm, 5 µm from Supelco). 183
The same mobile phases were used as for analytical HPLC and UV detection was carried out at 215 184 nm as well. Mass spectrometry (MS) was performed on a Micromass Q-Tof micro spectrometer with 185 electrospray ionization. Data collection and spectrum analysis were executed with Masslynx software. 186
Peptide synthesis 187
All peptides were manually synthesized by the 9-fluorenylmethyloxycarbonyl (Fmoc)-based solid 188 phase peptide synthesis (SPPS) on Rink Amide AM resin (ChemImpex, 0.45 -0.60 mmol g −1 ). For 189 standard couplings, Fmoc-protected amino acids (3 equiv) were sequentially coupled with TBTU (3 190 equiv) and DIPEA (9 equiv) for 1 h at room temperature (rt) in DMF. Fmoc deprotection was carried 191 out in a two-step manner (5 min and 15 min) by treating the resin with a 20% (v/v) 4-methyl-192 piperidine solution in DMF. After each coupling and Fmoc deprotection, the resin was washedM A N U S C R I P T
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thoroughly with DMF (3x) and DCM (3x). Amino acids containing an unprotected phenol in their side 194 chain [7-hydroxy-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (7-OH-Tic) and 2',6'-195 dimethyltyrosine (Dmt)] were coupled for 45 min at rt using a 2-fold excess of the Fmoc-protected 196 amino acid, HOBt (2 equiv) and DIC (2 equiv) in DMF. The same coupling conditions were in that 197 case used until completion of the peptide sequence, as well as when hydroxyl-containing 'peptoid' 198 residues were present in the sequence. 199 N-substituted glycines were prepared on the solid support using the following method: after Fmoc 200 deprotection, bromoacetylation of the amine was performed by adding 20 equiv of bromoacetic acid 201 and 25 equiv of DIC in DMF for 1 h. This mixture was filtered off and the resin was washed as 202 described above. Next, 20 equiv of the primary amine was added to the resin in DMSO and mixed for 203 1 h to introduce the side chain [27] . After insertion of the side chain, further peptide assembly was 204 continued as described above. 205
Acetylation of the N-terminus was performed with acetic anhydride (10 equiv) and DIPEA (5 equiv) 206 in DMF for 1 h. When unprotected reactive side chains were present, the acetylation was executed for 207 30 min with half of the standard amounts, more precisely 5 equiv of acetic anhydride and 2.5 equiv of 208 DIPEA. Cleavage from the resin and side chain deprotection were performed with TFA/TES/water 209 (95/2.5/2.5 v/v/v) at rt for 3 h. The resulting cleavage mixture was evaporated to remove the TFA. The 210 residue was next added to cold diethylether and centrifuged for 3 min at 3000 rpm. The precipitate was 211 redissolved in a mixture of water and ACN (1/1 v/v) and lyophilized. Finally, the crude peptide was 212 purified by preparative reversed phase HPLC (RP-HPLC) and lyophilized again. The structure of the 213 pure product was confirmed by high-resolution MS (HRMS). The purity of all peptides was more than 214 95% according to HPLC analysis. 215
Tritium labeling of NMU-8 216
Iodogen (0.92 µmol) was dissolved in 200 µL CH 2 Cl 2 and the solution was evaporated to dryness 217 under nitrogen in a reaction vial. NMU-8 (0.69 µmol) was dissolved in 1 mL of 50 mM Na 2 HPO 4 218 buffer pH 7.0 and the solution was added to the freshly prepared iodogen film. 2 µmol of NaI in 50 219 mM Na 2 HPO 4 buffer pH 7.0 was added and the mixture was stirred at rt for 1 min. Next, the solution 220 was removed and mixed with 125 µL of 2 mg/mL Na 2 S 2 O 5 in 50 mM Na 2 HPO 4 buffer pH 7.0. The 221 
Ci/mmol). 230
In vitro functional assay on NMUR1 and NMUR2 231
An inositol triphosphate (IP 3 ) SPA analysis was performed to study the functional activity of the novel 232 NMU-analogs at NMUR1 and NMUR2, since both receptors are described to signal mainly through 233 the Gα q/11 pathway [25, 28] . HEK293 cell cultures were maintained in DMEM with GlutaMAX TM , 234 supplemented with 10 % fetal bovine serum, 180 units/mL of penicillin and 45 µg/mL streptomycin. 235
These cultures were incubated at 37 °C with 10 % CO 2 and a relative humidity of 95 %. The HEK293 cells were incubated for 5 h at 37 °C. As a negative control, an empty vector (pcDNA) 248 transfection was carried out. The day after the transfection, cells were seeded out in transparent 96-249 well plates coated with poly-D-lysine with a density of 35 000 cells/well using culture medium 250 supplemented with 5 µL myo-[2-3 H(N)]inositol per mL. On the assay day, the plates were washed 251 twice with HBSS and incubated during 30 min at 37 °C with 100 µL/well of 10 mM lithium chloride 252 in HBSS. To each well, 5 µCi of a peptide solution was added and incubated for 60 min at 37 °C. 253
After peptide stimulation, the cells were lysed with 50 µL/well of 10 mM FA on ice for 30 min. 35 µL 254 of the lysates was transferred into white 96-well plates and 80 µL of SPA-yttrium silicate beads 255 solution was added to each well. The plates were sealed and shaken for 30 min. After spinning the 256 plates for 5 min at 1500 rpm, the decay was measured, with a delay of 8 h, during 2 min/well with the 257 Topcount (Packard Instrument Company, Meriden, Connecticut, USA). Each NMU analog was tested 258 in a concentration range of 10 -5 to 10 -11 M in at least 3 independent experiments using triplicates. 259
Competitive binding assay at NMUR1 and NMUR2 260
To evaluate the affinity of the novel NMU-analogs for the NMURs, a competitive binding study was 261 was tested in a concentration range of 10 -5 to 10 -11 M in at least 3 independent experiments using 271
triplicates. 272
In vitro plasma stability 273
An in vitro stability assay in human plasma was performed to study the effect of the introduced 274 modifications on enzymatic stability. Prior to the stability test, selectivity of the assay, stability of the 275 compound in the injection solvent, linearity, accuracy and precision of the method were investigated. 276
The NMU analogs were dissolved in water and consecutive dilutions were prepared with the same 277
solvent. An aqueous peptide solution was spiked in human plasma (10/90 v/v), which was incubated at 278 37 °C, with a final plasma concentration of 112 µM. Samples were taken at selected time points, 279 depending on the analyte (Supporting Information, Table S1 ), by transferring 100 µL of the spiked 280 plasma into a test tube and stopping the degradation process by adding 300 µL of methanol with 0.1% 281 Waters, Milford, Massachusetts, USA). For the calculation of the peptide half-life, only points with an 287 AUC higher than the AUC of the lowest standard were used. The concentrations were calculated by 288 use of the calibration curve and transferred to a semi-log chart presenting the log concentrations as a 289 function of time. To study the fragmentation profile, the samples were transferred to the LC-MS 290 system and the degradation products were identified by analyzing the m/z ratio of all peaks of the 291 spectrum. 292
Data analysis and statistical evaluation 293
Graphical representations and statistical evaluation were carried out with GraphPad Prism software 294 (San Diego, California, USA). EC 50 values were determined by nonlinear regression using sigmoidal 295 dose-response curve fit. Calculation of the IC 50 values was performed as well with sigmoidal dose-296 response curve fitting (variable slopes). Microsoft ® Office Professional 2010 Excel was used for 297 calculations of the peptide half-life. 298 M A N U S C R I P T
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Results and Discussion 299
Peptide synthesis 300
The truncated NMU-8 was taken as lead structure for the synthesis of all analogs, since it is a naturally 301 occurring form of the neuropeptide, of which the C-terminus is considered to be the critical part of the 302 peptide for receptor activation [3] . All targeted peptides were synthesized by Fmoc-based SPPS on 303
Rink Amide AM resin (vide supra) using TBTU as coupling reagent. The N-substituted glycines (the 304 so-called 'peptoid' residues) in peptides 31 -38 were prepared using the solid phase submonomer 305 method [27] . Amino acids with an unprotected phenol in their side chain (7-OH-Tic, Dmt) were 306 coupled using DIC/HOBt in order to prevent O-acylation. For these analogs, as well as for the 307 hydroxyl-containing peptoids, the remaining peptide sequence was assembled using the DIC/HOBt 308 mediated couplings. No difficulties were observed to couple Fmoc-Leu-OH to the secondary amine of 309 the peptoid residues. All peptides were purified to greater than 95% purity by RP-HPLC, and their 310 structure was confirmed by HRMS (Table S2, 
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Biological evaluation of the first set of NMU-analogs 322
Evaluation of the agonistic activities at the NMURs of the first set of NMU-analogs was performed in 323 the present study on HEK293 cells transiently expressing hNMUR1 or hNMUR2 using an inositol 324 triphosphate (IP 3 ) SPA assay. The affinity of a selection of analogs for the NMURs was determined in 325 these cells using competitive displacement with [
3 H]-NMU-8 as radioligand. Table 1 shows the results 326 for the modified peptides (Supporting information, Table S3 , for results presented as mean ± SEM). 327
N-terminal acetylation 328
It is reported that enzymatic degradation of the NMU-8 peptide mainly occurs via the N-terminus [14] . 329
With the aim to develop NMU-analogs possessing an increased stability, N-terminal modifications 330 were introduced in the peptide sequence. Sakura et al. described that acetylation of the N-terminal Tyr 1 331 leads to an increased resistance against proteolysis. Moreover, it has previously been shown that this 332 modification led to an increase in contractile activity on chicken crop smooth muscle preparations 333
[14]. In the present study, we evaluated Ac-NMU-8 (2) in an IP 3 accumulation assay on HEK293 cells, 334 an immediate read-out for receptor activation. The introduction of an acetyl group at the N-terminus 335 (2) led to a more than 40-fold increase in potency on both NMURs (with EC 50 values of 0.51 nM and 336 0.71 nM for NMUR1 and NMUR2, respectively) when compared to the native NMU-8 (1) (EC 50 = 337 38.9 nM for NMUR1 and 30.8 nM for NMUR2). N-terminal acetylation of 1 did not alter the affinity 338 for the NMURs. Acetylation of the N-terminus was systematically carried out in the current study, to 339 present both the acetylated and non-acetylated form of all analogs, and led in general to an increase of 340 the relative activity on both NMURs, when compared to the non-acetylated peptide. increased the potency for both receptors, although activity remained low, as compared to NMU-8. 348
However, partial agonists can be of therapeutic importance since they could be regarded as molecules 349 exerting both agonistic, when low levels of the endogenous ligand is present, and antagonist effects, 350 when present together with a full agonist competing for the same binding site [31] . 351
Chirality switches 352
A D-amino acid scan of NMU-8 was performed by Hashimoto et al. and tested on isolated chicken 353 crop smooth muscle preparations [13] . Inspired by the SAR studies which were performed in 'the 354 early days of NMU research', we decided to synthesize some of these analogs and evaluate them onM A N U S C R I P T found to be weak non-competitive antagonists in chicken crop preparations [13] . We included both 364 molecules and their N-terminal acetylated forms (compounds 7-10) in our study. These ligands indeed 365 did not show potent agonistic activity in the in vitro cell-based assays. To further investigate if these 366 molecules could act as antagonists on the NMURs, their ability to compete with radiolabeled agonist, 367
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[
3 H]-NMU-8, was evaluated. These compounds (7 -10) all showed a 1000-fold, or even higher, 368 decrease in affinity for NMUR1. On NMUR2, binding studies revealed a major loss in affinity, 369 ranging from a 400 to more than 3000-fold decrease. These results demonstrate that these 370 modifications lead to a loss in affinity and potency of the molecules. To our knowledge, no peptidergic 371 antagonists for NMUR1 or NMUR2 have been proven to exert activity in vivo until now. This 372 correlates with the observation that [D-Pro 6 ]-NMU-8 failed to exert antagonistic activity in vivo [32] . 373
However, a small molecule antagonist for NMUR2, R-PSOP, was reported by Liu et al [33] . 374
Replacing Arg 7 by D-Arg (11, 12) resulted in full agonists with an even higher intrinsic activity than 375 NMU-8 on NMUR2 (E max values of 131.1 % and 138.8 % for 11 and 12, respectively), but these 376 analogs gave way to a decrease in potency on both receptors. However, these molecules still possessed 377 similar potencies on NMUR1, as compared to the activity on NMUR2, they were only able to partially 378 activate this receptor. Finally, Takayama 
Biological evaluation of the second set of NMU-analogs 421
Substitution of the N-terminal tyrosine residue 422
To protect the peptides from cleavage by aminopeptidases, the N-terminus of NMU-8 was modified. 423 showed a very high, picomolar affinity for NMUR1, which is about ten times better than those of the 427 parent compounds 1 and 2, whereas their affinity for NMUR2 decreased. In the activity assay, they 428 were however non-selective, full agonists with a 15 % increase of the maximal effect at NMUR2 429 (Table 2 ). When Tyr 1 was replaced by 2'-naphtylalanine (2'Nal), a non-selective agonist for the 430
NMURs (17) with similar affinity and potency as compared to compound 1 was found. The acetylated 431 analog (18) however, is more potent than NMU-8 at NMUR1 and NMUR2, with a similar activity on 432 both receptors and a 6-fold higher affinity for NMUR1 (Table 2 and 
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The naturally constrained Pro 6 residue was replaced by the conformationally constrained 1,2,3,4-498 tetrahydroisoquinoline-3-carboxylic acid (Tic) residue. This bridged residue led to poor partial 499 NMUR1 agonists (39 and 40), which possessed a decreased receptor affinity as compared to NMU-8. 500
Although these analogs had a lower affinity for NMUR2 than compound 1, the non-acetylated peptide 501 was able to fully activate NMUR2 with only a 4.5 fold higher EC 50 value. Moreover, compound 40 502 was found to have a 2-fold higher potency at NMUR2, but it was not able to fully activate the receptor 503 (E max = 91.8 %). Similarly to the insertion of Tic at this position, replacement of Pro by Oic led to a 504 potent agonist (41) on NMUR2, even though it was already stated in literature that the Pro-Arg-Asn-505 NH 2 segment is critical for receptor activation [18] . Moreover, when this peptide was N-terminally 506 acetylated (42), the NMU-8 potency was exceeded. On NMUR1, the substitution of Pro by Oic led to 507 a full agonist with a 7-fold decrease in potency. However, when an acetylation was introduced at the 508 N-terminus, the NMU-8 potency was restored. Both compounds 41 and 42 possessed a decreased 509 affinity for the NMURs. Interestingly, modifications in this, previously described, critical part of the 510 NMU-8 sequence show that other cyclic amino acids are tolerated in this region of the peptide. 511
Substitution of Pro gave rise to molecules with an increased NMUR2 selectivity and high potency at 512 this receptor subtype, which makes it an attractive tool to further develop receptor subtype selective 513
analogs. 514
In vitro plasma stability 515
To evaluate the effect of the introduced modifications on the proteolytic stability of the NMU-analogs, 516
in vitro degradation studies in human plasma at 37 °C were performed on a selection of the novel 517 peptides. The percentage of the intact NMU-analog was measured over time by HPLC-UV analysis 518 ( Figure 5 ). Afterwards the samples were analyzed by means of MS and degradation profiles were 519 studied ( Figure 6 ). Depending on the stability of the peptide, samples were taken at different time 520 points (Table S1) . 521 NMU-8 (1) was characterized by a short half-life of only 4.3 ± 0.2 min. It was rapidly degraded at its 522 unprotected N-terminus where Tyr 1 was cleaved from the sequence. Since acetylation of the N-523 terminal amine was systematically performed on all NMU-analogs described in this study, the 524 resistance to biological degradation of compound 2 was evaluated next. When an acetyl group was 525 introduced at the N-terminus of the NMU-8 sequence, a more than 25-fold increase of the half-life 526 Previously, the stability of some NMU-based molecules was already reported in literature. Lipidation 564 of NMU-8 markedly increased its half-life in mouse plasma as compared to hNMU [21] . Moreover, 565 when the effect on proteolytic stability was studied of molecules without high molecular carriers, 566 improved resistance towards degradation was observed as well. The selective NMUR1 agonist, 2-567 thienylacetyl-Trp-(αMe)Trp-Arg-Pro-Arg-Asn-NH 2 , which was recently described by Takayama et al, 568 possessed an improved in vitro serum stability with a half-life of approximately 180 min [20] . Here, 569
we discovered molecules with plasma half-lifes up to 23 h. The potent NMUR1 agonist, compound 28, 570 possessed a half-life of 253.5 ± 6.0 min. In the present study, human plasma was used for the 571 determination of the biodegradation profiles. This does not allow direct comparison with the metabolic 572 stability of 2-thienylacetyl-Trp-(αMe)Trp-Arg-Pro-Arg-Asn-NH 2 , which was studied in serum. 573
Moreover, it was reported that the preferential biodegradation site of this NMUR1 selective agonist 574 was located between the Arg and Asn residues and that the key enzyme, responsible for this cleavage, 575 was found to be thrombin [20, 36] . The present study is giving more accurate information when 576 compared to studies where experiments were performed with 25% rat or human serum [19, 20] A novel set of NMU-analogs was developed and characterized in vitro. The core sequence of the 583 NMU-peptide, more precisely NMU-8, was taken as lead molecule for the SAR-study. Potent agonists 584 (compounds 15 -20), with equal activity on both NMURs, were obtained when the Tyr 1 residue was 585 modified, with affinities and activities in the nM range. Moreover, these peptides turned out to have an 586 elevated resistance against proteolytic degradation, resulting in molecules with an increased half-life in 587 human plasma. We demonstrated that substitution of Phe 4 could serve as a tool for NMUR1 selectivity 588 and improved plasma stability, which resulted in the discovery of potent NMU-analogs with increased 589 NMUR1 selectivity and enhanced stability in human plasma, more precisely analog 24, 26 and 28. By 590 synthesizing peptides with a modified Pro 6 residue, an increased potency on NMUR2 was observed. 591
Moreover, a remarkable effect on the enzymatic stability was found, going from 4 min for NMU-8 to 592 approximately 24 h for 42. By evaluating the effect of D-amino acid substitution on receptor affinity, 593
we demonstrated that the previously reported tool for antagonism led to a loss in affinity rather than 594 antagonism. We believe that this novel set of NMU-analogs can have potential in the development of 595 receptor selective NMU-based peptides with improved proteolytic stability. 596 M A N U S C R I P T
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